Pharmaceutical Technology

DECEMBER 16, 2022

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The figure below summarises the endometriosis market growth across the 7MM from 2020 to 2030. At the end of 2030, the US will contribute approximately 81.3% of 7MM sales.

Labelling 59

Labelling Compounding 59

European Pharmaceutical Review

FEBRUARY 8, 2023

Yescarta for blood cancer Yescarta is targeting expansions into the first line for diffuse large B-cell lymphoma (DLBCL) and second line for follicular lymphoma in 2030. Breyanzi will exhibit the largest compound annual growth rate (CAGR) at 30 percent, compared to Yescarta’s CAGR of 9 percent. Peak sales are anticipated to reach $1.3

Labelling 98

Labelling Compounding 98

Quality Matters

MARCH 1, 2024

USP has a long-standing history of healthcare standards including those for compounding preparations that are tailored to meet the unique needs of patients who may not otherwise have access to their medications. market by 2030, and this growth is not limited to the U.S., in the U.S.

Labelling 52

Labelling Compounding 52

PharmaShots

APRIL 3, 2023

The P-III trial (GUARD) results showed no safety signals & were found to be well tolerated with no observed treatment-emergent serious AEs ADX-2191 is a sterile, non-compounded IVT formulation of methotrexate for specific rare retinal diseases. old, for use by women with diabetes who are pregnant & for wear time of up to 15 days.

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40

Express Pharma

JANUARY 15, 2025

per cent expected from 2025 to 2030, the event will serve as a hub for Distributors, Procurement Managers, Product Development Experts, Regulatory Affairs Professionals, and R&D specialists. As the industry continues to grow, prioritising product quality, safety, and accurate labelling has become essential. In India, a nation of 1.4

Labelling 105

Labelling Immunity Immunization Compounding 105